RxDoctor Payments Data

Amanda Sterbenz, NP

Family · Brooklyn, NYNPI 1639608771

Payments from drug & device makers

$1,476in general payments, 2019–2025

Across 39 payments — averaging $37.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$658
  • Insulet Corporation$228
  • Merck$126
  • Corcept Therapeutics$118
  • Boehringer Ingelheim$80
  • Medtronic$54
  • plus $213 from 8 others

What the payments were for

  • Food & beverage$1,46299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,476 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$4,262
Medicare patients
29
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin435$323,806
TrulicityDulaglutide232$269,480
OzempicSemaglutide192$200,073
MounjaroTirzepatide73$78,002
ProliaDenosumab33$53,686
JanuviaSitagliptin Phosphate54$52,301
FarxigaDapagliflozin Propanediol44$34,496
JanumetSitagliptin Phos/Metformin Hcl47$31,893
RybelsusSemaglutide27$27,607
TradjentaLinagliptin23$17,247
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$14,638
Tresiba Flextouch U-100Insulin Degludec29$13,416
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp72$12,176
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$11,074
Novolog FlexpenInsulin Aspart50$6,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$80$341,053458 claims
MerckJanuvia, Janumet$126$84,194101 claims
AmgenProlia$658$53,68633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.

Other family in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →